4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidine-1-carboxylic acid tert-butyl ester | 808125-44-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-(2,7-diazatricyclo[7.3.1.05,13]trideca-1(12),5(13),6,8,10-pentaen-2-yl)piperidine-1-carboxylate
• CAS: 808125-44-2
• 化学式: C₂₁H₂₇N₃O₂
• 分子量: 353.464
• InChiKey: BQCLENWFHKQZQQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-(4-vinyl-5-isoquinolyl)amino-1-(tert-butoxycarbonyl)piperidine 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Tricyclic compound

  摘要：

  一个由以下公式表示的新化合物：[R1代表氢原子、氯原子或羟基；X1. . . X2代表—CH(R2)—CH(R3)—，—CH(R2)—CH(R3)—CH(R4)—等；R2到R4代表氢原子或烷基；A1、A11、A2和A21代表氢原子或烷基；Y代表—CH(A3)-，—CH(A3)-C(A4)(A41)-，—CH(A3)-C(A4)(A41)-C(A5)(A51)-或一个单键；A3、A4、A41、A5和A51代表氢原子或烷基；Z代表羟基或—N(A6)(A61)；A6代表氢原子或烷基，A61代表氢原子、烷基、芳烷基等；以及所述的一个或多个组合中的组合，选择自由基组合的组合，包括A6和A3、A6和A4、A6和A1、A6和A2、A2和A3、A2和A4、A6和A5、A3和A1、以及A5和A1，它们可以相互结合形成一个5-或6-成员环]，或其盐，它强力抑制肌球蛋白调节轻链的磷酸化。

  公开号：

  US20050096310A1

文献信息

• Nitrogen-containing tricyclic compounds
  申请人：Yamada Rintaro

  公开号：US20060247266A1

  公开（公告）日：2006-11-02

  A novel compound represented by the following formula (1) or a salt thereof [wherein R 1 , R 5 , R 6 , R 7 , and R 8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like; X 1 . . . X 2 represents —CH(R 2 )—CH(R 3 )—, —CH(R 2 )—CH(R 3 )—CH(R 4 )—, —C(R 2 )═C(R 3 )—, or —C(R 2 )═C(R 3 )—CH(R 4 )—(R 2 , R 3 , and R 4 represent hydrogen atom, or an alkyl group); A 1 , A 11 , A 2 , and A 21 represent hydrogen atom, or an alkyl group; Y represents —CH(A 3 )-, —CH(A 3 )-C(A 4 )(A 41 )-, —CH(A 3 )-C(A 4 )(A 41 )-C(A 5 )(A 51 )-, or a single bond (A 3 , A 4 , A 41 , A 5 , and A 51 represent hydrogen atom, or an alkyl group), and Z represents hydroxyl group, or —N(A 6 )(A 61 )(A 6 represents hydrogen atom, or an alkyl group, and A 61 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like)], having an action of potently inhibiting phosphorylation of myosin regulatory light chain.

  以下式（1）表示的新化合物或其盐[其中R1、R5、R6、R7和R8代表氢原子、卤素原子、羟基、烷基、烯基等；X1...X2代表—CH(R2)—CH(R3)—、—CH(R2)—CH(R3)—CH(R4)—、—C(R2)=C(R3)—或—C(R2)=C(R3)—CH(R4)—(R2、R3和R4代表氢原子或烷基)；A1、A11、A2和A21代表氢原子或烷基；Y代表—CH(A3)-、—CH(A3)-C(A4)(A41)-、—CH(A3)-C(A4)(A41)-C(A5)(A51)-或单一键（A3、A4、A41、A5和A51代表氢原子或烷基），Z代表羟基或—N(A6)(A61)(A6代表氢原子或烷基，A61代表氢原子、烷基、取代烷基等)]具有强烈抑制肌球蛋白调节轻链磷酸化的作用。
• NITROGENEOUS TRICYCLIC COMPOUND
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1829876A1

  公开（公告）日：2007-09-05

  A novel compound represented by the following formula (1) or a salt thereof [wherein R1, R5, R6, R7, and R8 represent hydrogen atom, a halogen atom, hydroxyl group, an alkyl group, an alkenyl group and the like; X1···X2 represents -CH(R2)-CH(R3)-, -CH(R2)-CH(R3)-CH(R4)-, -C(R2)=C(R3)-, or -C(R2)=C(R3)-CH(R4)- (R2, R3, and R4 represent hydrogen atom, or an alkyl group); A1, A11, A2, and A21 represent hydrogen atom, or an alkyl group; Y represents -CH(A3)-, -CH(A3)-C(A4)(A41)-, -CH(A3)-C(A4)(A41)-C(A5)(A51)-, or a single bond (A3, A4, A41, A5, and A51 represent hydrogen atom, or an alkyl group), and Z represents hydroxyl group, or -N(A6)(A61) (As represents hydrogen atom, or an alkyl group, and A61 represents hydrogen atom, an alkyl group, a substituted alkyl group and the like)], having an action of potently inhibiting phosphorylation of myosin regulatory light chain.

  由下式(1)代表的新型化合物或其盐[其中R1、R5、R6、R7和R8代表氢原子、卤素原子、羟基、烷基、烯基等；X1---X2代表-CH(R2)-CH(R3)-、-CH(R2)-CH(R3)-CH(R4)-、-C(R2)=C(R3)-或-C(R2)=C(R3)-CH(R4)-（R2、R3和R4代表氢原子或烷基）；A1、A11、A2和A21代表氢原子或烷基；Y 代表 -CH(A3)-、-CH(A3)-C(A4)(A41)-、-CH(A3)-C(A4)(A41)-C(A5)(A51)- 或单键（A3、A4、A41、A5 和 A51 代表氢原子或烷基），Z 代表羟基或 -N(A6)(A61) （As 代表氢原子、或烷基，A61 代表氢原子、烷基、取代的烷基等）]，具有有效抑制肌球蛋白调节轻链磷酸化的作用。
• US7160894B2
  申请人：——

  公开号：US7160894B2

  公开（公告）日：2007-01-09
• Tricyclic compound
  申请人：Yamada Rintaro

  公开号：US20050096310A1

  公开（公告）日：2005-05-05

  A novel compound represented by the formula (1): [R 1 represents hydrogen atom, chlorine atom, or hydroxyl group; X 1 . . . X 2 represents —CH(R 2 )—CH(R 3 )—, —CH(R 2 )—CH(R 3 )—CH(R 4 )—, etc.; R 2 to R 4 represent hydrogen atom, or an alkyl group; A 1 , A 11 , A 2 , and A 21 represent hydrogen atom, or an alkyl group; Y represents —CH(A 3 )-, —CH(A 3 )-C(A 4 )(A 41 )-, —CH(A 3 )-C(A 4 )(A 41 )-C(A 5 )(A 51 )-, or a single bond; A 3 , A 4 , A 41 , A 5 , and A 51 represent hydrogen atom, or an alkyl group; Z represents hydroxyl group, or —N(A 6 )(A 61 ); A 6 represents hydrogen atom, or an alkyl group, A 61 represents hydrogen atom, an alkyl group, an aralkyl group, etc.; and groups in each of one or more combinations selected from the group consisting of combinations of A 6 and A 3 , A 6 and A 4 , A 6 and A 1 , A 6 and A 2 , A 2 and A 3 , A 2 and A 4 , A 6 and A 5 , A 3 and A 1 , and A 5 and A 1 may bind to each other to form a 5- or 6-membered ring], or a salt thereof, which potently inhibits the phosphorylation of myosin regulatory light chain.

  一个由以下公式表示的新化合物：[R1代表氢原子、氯原子或羟基；X1. . . X2代表—CH(R2)—CH(R3)—，—CH(R2)—CH(R3)—CH(R4)—等；R2到R4代表氢原子或烷基；A1、A11、A2和A21代表氢原子或烷基；Y代表—CH(A3)-，—CH(A3)-C(A4)(A41)-，—CH(A3)-C(A4)(A41)-C(A5)(A51)-或一个单键；A3、A4、A41、A5和A51代表氢原子或烷基；Z代表羟基或—N(A6)(A61)；A6代表氢原子或烷基，A61代表氢原子、烷基、芳烷基等；以及所述的一个或多个组合中的组合，选择自由基组合的组合，包括A6和A3、A6和A4、A6和A1、A6和A2、A2和A3、A2和A4、A6和A5、A3和A1、以及A5和A1，它们可以相互结合形成一个5-或6-成员环]，或其盐，它强力抑制肌球蛋白调节轻链的磷酸化。